Transaction details
AQR Capital Management, together with AQR Capital Management Holdings, LLC and AQR Arbitrage LLC, completed the sale of 4,619 shares of common stock in IB Acquisition Corp. (NASDAQ: IBAC) on March 20, 2026. The shares changed hands at $10.75 each, producing a total transaction value of $49,654. The selling entities serve as investment managers to AQR DELTA Master Account, L.P., and, according to the filing, they no longer hold any IBAC shares following this disposition.
Market context and valuation note
IB Acquisition's shares are trading at $11, which places the stock close to its 52-week high of $11.45. The company carries a market capitalization of $61.68 million. Analysis reported by InvestingPro describes IBAC as appearing overvalued at current levels and places the security among the most overvalued names tracked by that platform.
Corporate developments at IB Acquisition
Separately from the AQR sale, IB Acquisition Corp. has announced a major pending deal. The company is set to acquire GNQ Insilico Inc., a Canada-based artificial intelligence drug development company, in a transaction valued at $500 million. That deal has the backing of a majority of GNQ shareholders and is expected to close in the third quarter of 2026.
GNQ Insilico has also entered into a strategic collaboration with a Fortune 100 global technology company. That partnership is intended to advance AI-driven drug discovery and precision medicine initiatives by combining GNQ's AI platforms with the partner's consulting, cloud, and quantum computing capabilities.
Other related corporate and audit updates
In related activity within the blank-check and acquisition vehicle space, Invest Acquisition Corp appointed CBIZ CPAs as its new auditor following CBIZ's acquisition of Marcum LLP's attest business. The auditor change was effective January 14, 2026, with Marcum LLP continuing to serve as auditor up to that date.
Also noted in market filings, Iris Acquisition Corp II completed an initial public offering that raised $168.5 million through the sale of 16,850,000 units. Each unit consists of one Class A ordinary share and one-half of one redeemable warrant.
Key takeaways
- AQR-related entities sold 4,619 IBAC shares on March 20, 2026, at $10.75 per share, totaling $49,654.
- After the sale, the AQR-managed account holds no IBAC stock.
- IB Acquisition continues a planned $500 million purchase of GNQ Insilico Inc., supported by a majority of GNQ shareholders and targeted to close in Q3 2026.
Risks and uncertainties
- Valuation risk - InvestingPro flags IBAC as appearing overvalued at current prices, which may affect investor sentiment toward the stock.
- Deal completion risk - The GNQ Insilico acquisition is expected to close in Q3 2026, and its completion remains a scheduled future event.
- Audit transition - The change in auditor for Invest Acquisition Corp could introduce operational or reporting adjustments following the transition that became effective January 14, 2026.
Summary statement
The filing documents a modest but complete divestiture of IBAC shares by AQR-affiliated managers and occurs as IB Acquisition pursues a material acquisition in the AI-driven drug development sector and other corporate housekeeping actions are recorded in the acquisition vehicle market.